1600563-62-9Relevant academic research and scientific papers
Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt
Kummer, David A.,Cummings, Maxwell D.,Abad, Marta,Barbay, Joseph,Castro, Glenda,Wolin, Ronald,Kreutter, Kevin D.,Maharoof, Umar,Milligan, Cynthia,Nishimura, Rachel,Pierce, Joan,Schalk-Hihi, Celine,Spurlino, John,Urbanski, Maud,Venkatesan, Hariharan,Wang, Aihua,Woods, Craig,Xue, Xiaohua,Edwards, James P.,Fourie, Anne M.,Leonard, Kristi
, p. 2047 - 2057 (2017/04/10)
A high-throughput screen of the ligand binding domain of the nuclear receptor retinoic acid-related orphan receptor gamma t (RORγt) employing a thermal shift assay yielded a quinoline tertiary alcohol hit. Optimization of the 2-, 3- and 4-positions of the quinoline core using structure-activity relationships and structure-based drug design methods led to the discovery of a series of modulators with improved RORγt inhibitory potency and inverse agonism properties.
6-Substituted quinolines as RORγt inverse agonists
Barbay, J. Kent,Cummings, Maxwell D.,Abad, Marta,Castro, Glenda,Kreutter, Kevin D.,Kummer, David A.,Maharoof, Umar,Milligan, Cynthia,Nishimura, Rachel,Pierce, Joan,Schalk-Hihi, Celine,Spurlino, John,Tanis, Virginia M.,Urbanski, Maud,Venkatesan, Hariharan,Wang, Aihua,Woods, Craig,Wolin, Ronald,Xue, Xiaohua,Edwards, James P.,Fourie, Anne M.,Leonard, Kristi
, p. 5277 - 5283 (2017/10/30)
We identified 6-substituted quinolines as modulators of the retinoic acid receptor-related orphan receptor gamma t (RORγt). The synthesis of this class of RORγt modulators is reported, and optimization of the substituents at the quinoline 6-position that
HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
-
, (2014/05/07)
The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
